Skip to main content
Top
Published in: BMC Infectious Diseases 1/2015

Open Access 01-12-2015 | Research article

Antibiotic use for Vibrio infections: important insights from surveillance data

Authors: Kam Cheong Wong, Anthony M. Brown, Georgina M. Luscombe, Shin Jie Wong, Kumara Mendis

Published in: BMC Infectious Diseases | Issue 1/2015

Login to get access

Abstract

Background

There is a paucity of data on the in vivo efficacy of antibiotics for lethal Vibrio species. Analyses of long-term surveillance datasets may provide insights into use of antibiotics to decrease mortality.

Methods

The United States Centers for Disease Control and Prevention (CDC) Cholera and Other Vibrio Illness Surveillance (COVIS) dataset from 1990 to 2010, with 8056 records, was analysed to ascertain trends in antibiotics use and mortality.

Results

Two-thirds of patients (5243) were prescribed antibiotics - quinolones (56.1 %), cephalosporins (24.1 %), tetracyclines (23.5 %), and penicillins (15.4 %). Considering all Vibrio species, the only class of antibiotic associated with reduced odds of mortality was quinolone (odds ratio 0.56, 95 % CI 0.46-0.67). Patients with V. vulnificus treated according to CDC recommendations had lower mortality (quinolone alone: 16.7 %, 95 % CI 10.2-26.1; tetracycline plus cephalosporin: 21.7 %, 16.8-27.5; no antibiotic: 51.1 %, 45.6-56.7; each p < 0.001). Cephalosporin alone was associated with higher mortality (36.8 %, 28.2-46.3). For V. cholerae non-O1, non-O139, mortality rates were lower for quinolone (0 %, 0–2.0) or tetracycline (4.3 %, 1.2-14.5) compared to no antibiotic (9.3 %, 6.4-13.3). For all Vibrio species, mortality rates increased with number of antibiotics in the treatment regimen (p < 0.001). Treatment regimens that included quinolone were associated with lower mortality rates regardless of the number of antibiotics used. The main clinical syndromes of patients with V. vulnificus infection were septicaemia (53.1 %) and wound infections (30.6 %). Mortality among V. vulnificus patients with septicaemia was significantly higher than for other clinical syndromes (p < 0.001). In a multivariate regression model, mortality in cases with V. vulnificus was associated with presence of pre-existing conditions (ORs ranged from 4.52 to 10.30), septicaemia (OR 2.64, 95 % CI 1.92-3.63) and no antibiotic treatment (OR 7.89, 95 % CI 3.94-15.80).

Conclusion

In view of the lack of randomized control trials, surveillance data may inform treatment decisions for potentially lethal Vibriosis. Considering all Vibrio species, use of quinolones is associated with lower mortality and penicillin alone is not particularly effective. For the most lethal species, V. vulnificus, treatment that includes either quinolone or tetracycline is associated with lower mortality than cephalosporin alone. We recommend treating patients who present with a clinical syndrome suggestive of V. vulnificus infection with a treatment regimen that includes a quinolone.
Literature
1.
go back to reference Newton A et al. Increasing rates of vibriosis in the United States, 1996–2010: review of surveillance data from 2 systems. Clin Infect Dis. 2012;54 Suppl 5:S391–5.CrossRefPubMedPubMedCentral Newton A et al. Increasing rates of vibriosis in the United States, 1996–2010: review of surveillance data from 2 systems. Clin Infect Dis. 2012;54 Suppl 5:S391–5.CrossRefPubMedPubMedCentral
2.
5.
6.
go back to reference Nelson EJ et al. Antibiotics for both moderate and severe cholera. N Engl J Med. 2011;364(1):5–7.CrossRefPubMed Nelson EJ et al. Antibiotics for both moderate and severe cholera. N Engl J Med. 2011;364(1):5–7.CrossRefPubMed
7.
8.
go back to reference Horseman, M.A. and S. Surani. A comprehensive review of Vibrio vulnificus: an important cause of severe sepsis and skin and soft-tissue infection. Int J Infect Dis. 15(3): p. e157-66. Horseman, M.A. and S. Surani. A comprehensive review of Vibrio vulnificus: an important cause of severe sepsis and skin and soft-tissue infection. Int J Infect Dis. 15(3): p. e157-66.
10.
go back to reference Dechet AM et al. Nonfoodborne Vibrio infections: an important cause of morbidity and mortality in the United States, 1997–2006. Clin Infect Dis. 2008;46(7):970–6.CrossRefPubMed Dechet AM et al. Nonfoodborne Vibrio infections: an important cause of morbidity and mortality in the United States, 1997–2006. Clin Infect Dis. 2008;46(7):970–6.CrossRefPubMed
12.
go back to reference Highly invasive new bacterium isolated from US east coast waters. JAMA, National Institutes of Health. 1984. 251(3): p. 323–5. Highly invasive new bacterium isolated from US east coast waters. JAMA, National Institutes of Health. 1984. 251(3): p. 323–5.
13.
go back to reference Morris Jr JG, Tenney J. Antibiotic therapy for Vibrio vulnificus infection. JAMA. 1985;253(8):1121–2.CrossRefPubMed Morris Jr JG, Tenney J. Antibiotic therapy for Vibrio vulnificus infection. JAMA. 1985;253(8):1121–2.CrossRefPubMed
14.
go back to reference Shaw, K.S., et al. Antimicrobial susceptibility of vibrio vulnificus and vibrio parahaemolyticus recovered from recreational and commercial areas of chesapeake bay and maryland coastal bays PLOS One, 2014. 9(2):e89616. Shaw, K.S., et al. Antimicrobial susceptibility of vibrio vulnificus and vibrio parahaemolyticus recovered from recreational and commercial areas of chesapeake bay and maryland coastal bays PLOS One, 2014. 9(2):e89616.
15.
go back to reference Linder JA et al. Fluoroquinolone prescribing in the United States: 1995 to 2002. Am J Med. 2005;118(3):259–68.CrossRefPubMed Linder JA et al. Fluoroquinolone prescribing in the United States: 1995 to 2002. Am J Med. 2005;118(3):259–68.CrossRefPubMed
16.
go back to reference Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA. 2000;283(3):373–80.CrossRefPubMed Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA. 2000;283(3):373–80.CrossRefPubMed
17.
18.
go back to reference Bullen JJ et al. Hemochromatosis, iron and septicemia caused by Vibrio vulnificus. Arch Intern Med. 1991;151(8):1606–9.CrossRefPubMed Bullen JJ et al. Hemochromatosis, iron and septicemia caused by Vibrio vulnificus. Arch Intern Med. 1991;151(8):1606–9.CrossRefPubMed
19.
go back to reference Hlady WG, Klontz KC. The epidemiology of Vibrio infections in Florida, 1981–1993. J Infect Dis. 1996;173(5):1176–83.CrossRefPubMed Hlady WG, Klontz KC. The epidemiology of Vibrio infections in Florida, 1981–1993. J Infect Dis. 1996;173(5):1176–83.CrossRefPubMed
20.
go back to reference Brennt CE et al. Growth of Vibrio vulnificus in serum from alcoholics: association with high transferrin iron saturation. J Infect Dis. 1991;164(5):1030–2.CrossRefPubMed Brennt CE et al. Growth of Vibrio vulnificus in serum from alcoholics: association with high transferrin iron saturation. J Infect Dis. 1991;164(5):1030–2.CrossRefPubMed
21.
go back to reference Blake PA et al. Disease caused by a marine Vibrio Clinical characteristics and epidemiology. N Engl J Med. 1979;300(1):1–5.CrossRefPubMed Blake PA et al. Disease caused by a marine Vibrio Clinical characteristics and epidemiology. N Engl J Med. 1979;300(1):1–5.CrossRefPubMed
22.
go back to reference Weis, K.E., et al. Vibrio illness in Florida, 1998–2007. Epidemiol Infect. 2011;139(4): p. 591–8. Weis, K.E., et al. Vibrio illness in Florida, 1998–2007. Epidemiol Infect. 2011;139(4): p. 591–8.
Metadata
Title
Antibiotic use for Vibrio infections: important insights from surveillance data
Authors
Kam Cheong Wong
Anthony M. Brown
Georgina M. Luscombe
Shin Jie Wong
Kumara Mendis
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2015
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-015-0959-z

Other articles of this Issue 1/2015

BMC Infectious Diseases 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine